Cambridge, United Kingdom
Mogrify is leveraging its proprietary platform technologies to revolutionize treatment methods for degenerative diseases through a new class of in vivo reprogramming therapies. Established in 2019 and headquartered in the United Kingdom, the company has positioned itself to penetrate the burgeoning regenerative medicine market, anticipated to reach $150 billion USD by 2028.
With its slogan, "Transforming the lives of patients with degenerative diseases through a novel class of in vivo reprogramming therapies," Mogrify aims to redefine possibilities in cell therapy. Their platforms, MOGRIFY® and epiMOGRIFY®, are rooted in extensive research and data science, enabling precise and predictive cell reprogramming.
To date, the startup has secured over $40 million USD in funding from investors including Parkwalk, Ahren Innovation Capital, and Astellas Venture Management, with the latest round being a $10.00M Series A investment as of October 2, 2023. Their commercialization strategy combines therapy development and strategic partnerships, maximizing the utility of their platform.
